NPSP
In August, I reported:
First suggested here at $6.65 and then again at $5.50 or so, NPSP closed Friday at $22.59, for about a quadruple. I celebrated by taking some profits; yet Guru writes of the company’s wildly expensive drug ($295,000 a year): “There are probably 1,000 to 3,000 people in the US who could really benefit from Gattex. Could be more. That’s $300 million to $900 million in the US. They will launch in Europe where the market is similarly sized. For sure this is a $500 million in peak sales. Every year. For a long time. No competition. No one even trying to compete. This product could extend survival. Meanwhile, they have another product, for hypoparathyroidism — to supply the missing parathyroid hormone. Will file this year. Launch end of next year. Another $300 million potential market in the US. Then they get a royalty from Amgen of $100 million. The stock should hit 36 over the next year.” So I’ve kept some.
Yesterday, it closed at $35.11, which is close enough. I took my six-fold gain (thanks, Guru) and sold the rest.
Have a great day. I feel a political screed coming on, but for now, you’re spared.
Quote of the Day
When you have nothing to say, sing it.
~Old Madison Avenue adageSearch
Request email delivery
Recent Posts
- Apr 12:
An App You’ll Want To Check Out - Apr 9:
Demented Agents; Brain HQ - Apr 8:
Barney’s Excellent Advice - Apr 7:
The Latest From Mystic Mag - Apr 6:
Boehner And More - Apr 5:
The Details Can Be A Little Challenging To Work Out, But . . . - Apr 2:
Fixing Our Infrastructure . . . And Our Soul - Apr 1:
Fun And Fraud - Mar 31:
How’s Your Elevator Pitch? - Mar 30:
Silt Accumulates
- Apr 12: